Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (PSMA-PRED)

NCT06600802 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT06600802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06600802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (PSMA-PRED)
Lead sponsor
Centre Jean Perrin
Phase
Not applicable
Overall status
Recruiting
Start date
October 8, 2024
Completion date
June 30, 2034
Enrollment
120 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant metastatic prostate cancer, treated by 177lutetium-psma-617 (lu-psma)